CN1471395A - 阿扑吗啡衍生物及其使用方法 - Google Patents

阿扑吗啡衍生物及其使用方法 Download PDF

Info

Publication number
CN1471395A
CN1471395A CNA01815168XA CN01815168A CN1471395A CN 1471395 A CN1471395 A CN 1471395A CN A01815168X A CNA01815168X A CN A01815168XA CN 01815168 A CN01815168 A CN 01815168A CN 1471395 A CN1471395 A CN 1471395A
Authority
CN
China
Prior art keywords
apomorphine
sulfate
patient
treatment
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA01815168XA
Other languages
English (en)
Chinese (zh)
Inventor
Pk
P·K·古普塔
ؿƷ�˹��-��˹�ķ
D·苏特科夫斯基－马克哈姆
�Ʒ�
D·米尔科夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tap Pharmaceuticals Inc
Original Assignee
Tap Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceuticals Inc filed Critical Tap Pharmaceuticals Inc
Publication of CN1471395A publication Critical patent/CN1471395A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CNA01815168XA 2000-04-07 2001-03-29 阿扑吗啡衍生物及其使用方法 Pending CN1471395A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19565000P 2000-04-07 2000-04-07
US60/195,650 2000-04-07

Publications (1)

Publication Number Publication Date
CN1471395A true CN1471395A (zh) 2004-01-28

Family

ID=22722192

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA01815168XA Pending CN1471395A (zh) 2000-04-07 2001-03-29 阿扑吗啡衍生物及其使用方法

Country Status (18)

Country Link
US (1) US6506765B2 (enExample)
EP (1) EP1284735A4 (enExample)
JP (1) JP2003532640A (enExample)
KR (1) KR20030036157A (enExample)
CN (1) CN1471395A (enExample)
AU (1) AU2001255818A1 (enExample)
BG (1) BG107217A (enExample)
BR (1) BR0109515A (enExample)
CA (1) CA2405419A1 (enExample)
CZ (1) CZ20023637A3 (enExample)
HU (1) HUP0301773A3 (enExample)
IL (1) IL151614A0 (enExample)
MX (1) MXPA02009904A (enExample)
NO (1) NO20024806D0 (enExample)
PL (1) PL361672A1 (enExample)
SK (1) SK15772002A3 (enExample)
WO (1) WO2001076602A1 (enExample)
ZA (1) ZA200207489B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002934D0 (sv) * 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2479372A1 (en) * 2002-03-19 2003-10-02 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
WO2004069167A2 (en) * 2003-01-31 2004-08-19 Nastech Pharmaceutical Company Inc. Method and compositions for treating male infertility
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
PT2450041T (pt) 2005-10-12 2018-11-16 Unimed Pharmaceuticals Llc Gel de testosterona melhorado e método para a sua utilização
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
US10729710B2 (en) 2017-11-24 2020-08-04 H. Lundbeck A/S Catecholamine prodrugs for use in the treatment of Parkinson's disease
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
EP3972970A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
EP3972971A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's diseases
EP3972959A1 (en) 2019-05-21 2022-03-30 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
US20240335379A1 (en) * 2021-08-05 2024-10-10 Zydus Lifesciences Limited Stable pharmaceutical compositions of apomorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
DK0689438T3 (da) 1993-03-26 2003-09-29 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af apomorfin
ES2143049T3 (es) 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
EP1089736A2 (en) * 1998-06-22 2001-04-11 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
IT1299566B1 (it) * 1998-07-17 2000-03-16 Ifi Istituto Farmacoterapico I Cerotto transdermico e composizioni farmaceutiche comprendenti r (-)- norapropilapomorfina cloridrato e/o s (+) - norapropilapomorfina
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
MXPA01011480A (es) * 1999-05-13 2002-06-04 Unihart Corp Composiciones farmaceuticas que comprenden apocodeina y/o sus derivados.

Also Published As

Publication number Publication date
HUP0301773A3 (en) 2006-02-28
EP1284735A4 (en) 2006-01-11
ZA200207489B (en) 2003-12-18
AU2001255818A1 (en) 2001-10-23
PL361672A1 (en) 2004-10-04
EP1284735A1 (en) 2003-02-26
US6506765B2 (en) 2003-01-14
WO2001076602A1 (en) 2001-10-18
SK15772002A3 (sk) 2003-09-11
NO20024806D0 (no) 2002-10-04
IL151614A0 (en) 2003-04-10
JP2003532640A (ja) 2003-11-05
BG107217A (bg) 2003-05-30
MXPA02009904A (es) 2004-09-06
CZ20023637A3 (cs) 2003-02-12
US20020002176A1 (en) 2002-01-03
HUP0301773A2 (hu) 2003-09-29
KR20030036157A (ko) 2003-05-09
BR0109515A (pt) 2004-08-10
CA2405419A1 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
CN1471395A (zh) 阿扑吗啡衍生物及其使用方法
JP5528705B2 (ja) ヒトにおける早漏を治療するための方法
CN1335772A (zh) 阿扑吗啡在制备治疗男性器质性勃起障碍的药物中的应用
US20020006933A1 (en) Method for treating sexual dysfunction with apomorphine at specified plasma concentration levels
US6528521B2 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
WO2002024202A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
JP2014505113A (ja) 末梢作用性μオピオイドアンタゴニスト
NZ544484A (en) Treatment of premature ejaculation
KR101082802B1 (ko) 8-하이드록시클로미프라민 또는 그의 염을 포함하는 조루의 예방 또는 치료용 약학 조성물
US20020086876A1 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
TWI907146B (zh) 3-[(苯並[d][1,3]二氧戊環-4-基)-氧基]-3-芳基丙胺類化合物在製備治療性功能障礙的藥物中的用途
TW202519202A (zh) 3-[(苯並[d][1,3]二氧戊環-4-基)-氧基]-3-芳基丙胺類化合物在製備治療性功能障礙的藥物中的用途
AU2005100183A4 (en) Treatment of premature ejaculation
JP2002255820A (ja) モノアミン作動性神経の活性化剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication